Crater GD, Lalonde K, Ravenelle F, Harvey M, et al. Effects of CB1R inverse agonist, INV-202, in patients with features of metabolic syndrome. A randomized, placebo-controlled, double-blind phase 1b study. Diabetes Obes Metab 2024;26:642-649.
PMID: 37941317